Pathogenesis of psoriasis
Keywords:
Psoriasis, pathogenesis, immunity, inflammation, T lymphocytes, biological agentsAbstract
Psoriasis is a common, disfiguring, inflammatory and proliferative condition of the skin, inwhich both genetic and environmental influences have a critical role. The disease had beentraditionally considered as a hyperproliferative disorder and various treatment modalitiessupposedly had anti-proliferative actions. Recently the advances in molecular techniqueshave given a new view regarding the pathogenesis of the disease. Now there is considerableevidence to suggest that psoriasis is a T-cell mediated inflammatory disease and varioustreatment options are now becoming available which effect different steps of this immunemechanism. Considering the importance of psoriasis it is considered mandatory to review therecently revised pathogenesis of the disease along with a brief description of the mechanismof action of various biological agents which are being used in the treatment.References
Krueger JG. The immunologic basis
for the treatment of psoriasis with new
biological agents. J Am Acad
Dermatol 2002; 46: 1-23.
Capon F, Munro M, Barker J,
Trembath R. Searching for the major
histocompatibility complex psoriasis
susceptibility gene. J Invest Dermatol
; 118: 745-51.
Trembath RC, Clough RL, Rosbotham
JL et al. Identification of a major
susceptibility locus on chromosome
p and evidence for further disease
loci revealed by a two-stage genomewide
search in psoriasis. Hum Mol
Genet 1997; 6: 813-20.
Tomfohrde J, Silverman A, Barnes R
et al. Gene for familial psoriasis
susceptibility mapped to the distal end
of human chromosome 17q. Science
; 264: 1141-5.
Mathews D, Fry L, Powles A et al.
Evidence that a locus for familial
psoriasis maps to chromosome 4q. Nat
Genet 1996; 14: 231-3.
Capon F, Novelli G, Semprini S et al.
Searching for psoriasis susceptibility
genes in Italy: genome scan and
evidence for a new locus on
chromosome 1. J Invest Dermatol
; 112: 32-5.
Enlund F, Samuelsson L, Enerback C
et al. Psoriasis susceptibility locus in
chromosome region 3q21 identified in
patients from southwest Sweden. Eur J
Hum Genet 1999; 7: 783-90.
Lee YA, Ruschendorf F, Windemuth
C et al. Genomewide scan in German
families reveals evidence for a novel
psoriasis-susceptibility locus on
chromosome 19p13. Am J Hum Genet
; 67: 1020-4.
Veal CD, Clough RL, Barber RC et al.
Identification of novel psoriasis
susceptibility locus at 1p and evidence
of epistasis between PSORS1 and
candidate loci. J Med Genet 2001; 38:
-13.
Karason A, Gudjonsson JE, Upmanyu
R et al. A susceptibility gene for
psoriatic arthritis maps to
chromosome 16q: evidence for
imprinting. Am J Hum Genet 2003;
: 125-31.
Mansbridge JN, Knapp AM. Changes
in keratinocyte maturation during
wound healing. J Invest Dermatol
; 89: 253-63.
de Rie MA, Bos JD. Immunological
aspects of psoriasis. Neth J Med 1998;
; 143-4.
van de Kerkhof PCM. Pathogenesis.
In: van de Kerkhof PCM, ed. Textbook
of Psoriasis. Oxford: Blackwell
Science; 1999. p. 79-105.
Nickoloff BJ. The immunologic and
genetic basis of psoriasis. Arch
Dermatol 1999; 135: 1104-10.
Elder JT, Fisher GJ, Lindquist PB et
al. Overexpression of transforming
growth factor-a in psoriatic epidermis.
Science 1989; 243: 811-4.
Creamer D, Allen MH, Sousa A et al.
Localization of endothelial
proliferation and microvascular
expansion in active plaque psoriasis.
Br J Dermatol 1997; 136: 859-65.
Goodfield M, Hull SM, Holland D et
al. Investigations of the ‘active’ edge
of plaque psoriasis: vascular
proliferation precedes changes in
epidermal keratin. Br J Dermatol
; 131: 808-13.
Nickoloff BJ, Mitra RS, Varani J et al.
Aberrant production of interleukin-8
and thrombospondin-1 by psoriatic
keratinocytes mediates angiogenesis.
Am J Pathol 1994; 144: 820-8.
Detmar M, Brown LF, Claffey KP et
al. Overexpression of vascular
permeability factor/vascular
endothelial growth factor and its
receptors in psoriasis. J Exp Med
; 180: 1141-6.
Creamer D, Allen M, Jaggar R et al.
Mediation of systemic vascular
hyperpermeability in severe psoriasis
by circulating vascular endothelialgrowth factor. Arch Dermatol 2002;
: 791-6.
Barker JNWN. The pathophysiology
of psoriasis. Lancet 1993; 338: 227-
Braun-Falco O, Schmoeckel C. The
dermal inflammatory reaction in initial
psoriatic lesions. Arch Dermatol Res
; 258; 9-16.
Bjerke JR, Krogh HK, Matre R.
Characterization of mononuclear cell
infiltrates in psoriatic lesions. J Invest
Dermatol 1978; 71: 340-3.
Krogh HK, Bjerke JR. Identification
of subpopulation of mononuclear cells
in psoriatic lesions. Acta Derm
Venereol 1979; 87: 21.
Bos JD, Hulsebosch HJ, Krieg SR et
al. Immunocompetent cells in
psoriasis. In situ immunophenotyping
by monoclonal antibodies. Arch
Dermatol Res 1983; 275: 181-9.
Gottlieb AB, Lifshitz B, Fu SM et al.
Expression of HLA-DR molecules by
keratinocytes, and presence of
Langerhans cells in the dermal
infiltrate of active psoriatic plaques. J
Exp Med 1986; 164: 1013-28.
Baker B, Valdimarsson H, Leonard JN
et al. The action of topical steroids,
dithranol and PUVA on Tlymphocytes
and dendritic cells in
psoriasis. Br J Dermatol 1984; 111:
Baker BS, Swain AF, Griffiths CEM
et al. Epidermal T lymphocytes and
dendritic cells in chronic plaque
psoriasis: the effects of PUVA
treatment. Clin Exp Immunol 1985;
: 526-34.
Bos JD. The pathomechanisms of
psoriasis: the skin immune system and
cyclosporin. Br J Dermatol 1988; 118:
-55.
Khandke L, Krane JF, Ashinoff R et
al. Cyclosporine in psoriasis
treatment: Inhibition of keratinocyte
cell-cycle progression in G1
independent of effects on transforming
growth factor alpha/epidermal growth
factor receptor pathways. Arch
Dermatol 1991; 127: 1172-9.
Flerlbeck G, Rassner G, Muller C.
Psoriasis induced at the injection site
of recombinant interferon gamma:
results of immunohistologic
investigations. Arch Dermatol 1990;
: 351-5.
Systemic tacrolimus (FK 506) is
effective for the treatment of psoriasis
in a double-blind placebo-controlled
study. The European FK 506
Multicentre Psoriasis Study Group.
Arch Dermatol 1996; 132: 419-23.
Wrone-Smith T, Nickoloff BJ. Dermal
injection of immunocytes induces
psoriasis. J Clin Invest 1996; 98:1878-
Banchereau J, Steinman RM.
Dendritic cells and the control of
immunity. Nature 1998; 392: 245-52.
Dieu-Nosjean MC, Massacrier C,
Homy B et al. Macrophage
inflammatory protein 3 alpha is
expressed at inflamed epithelial
surfaces and is the most potent
chemokine known in attracting
Langerhans cell precursors. J Exp Med
; 192: 705-78.
Valdimarsson H, Sigmundsdottir H,
Jonsdottir I. Is psoriasis induced by
streptococcal superantigens and
maintained by M-protein-specific T
cells that cross react with keratin? Clin
Exp Immunol 1997; 107 (Suppl.1): 21-
Berridge MJ. Lymphocyte activation
in health and disease. Crit Rev
Immunol 1997; 17: 155-78.
Thompson CB, Lindsten T, Ledbetter
JA et al. CD28 activation pathway
regulates the production of multiple Tcell
derived lymphokines/cytokines.
Proc Nat Acad Sci USA 1989; 86:
-7.
Fraser JD, Weiss A. Regulation of Tcell
lymphokine gene transcription by
the accessory molecule CD28. Mol
Cell Biol 1992; 12: 4357-63.
Hollenbaugh D, Ochs HD, Noelle RJ
et al. The role of CD40 and its ligands
in the regulation of the immune
response. Immunol Rev 1994; 138: 23-
Szaboics P, Avigan D, Gezelter S et
al. Dendritic cells and macrophages
can mature independently from human
bone marrow-derived, post-colonyforming
unit intermediate. Blood
; 87: 4520-30.
O’Doherty U, Ignatius R, Bhardwaj N,
Pope M. Generation of monocyte derived dendritic cells from precursors
in rhesus macaque blood. J Immunol
Methods 1997; 207: 185-94.
Cella M, Scheidegger D, Palmer-
Lehmann K et al. Ligation of CD40
on dendritic cells triggers production
of high levels of interleukin-12 and
enhances T cell stimulatory capacity:
T-T help via APC activation. J Exp
Med 1996; 184: 747-52.
Mosmann TR, Sad S. The expanding
universe of T-cell subsets: Th1, Th2
and more. Immunol Today 1996; 17:
-46.
Ullrich SE. Mechanism involved in
the systemic suppression of antigen -
presenting cell function by UV
irradiation: keratinocyte-derived IL–
modulates antigen–presenting cell
function of splenic adherent cells. J
Immunol 1994; 152: 3410-6.
Nickolloff BJ. The immunologic and
genetic basis of psoriasis. Arch
Dermatol 1999; 135:1104-10.
Schlaak JF, Buslau M, Jochum W et
al. T cells involved in psoriasis
vulgaris belong to the Th1 subset. J
Invest Dermatol 1994; 102: 145-9.
Austin LM, Coven TR, Bhardwaj N et
al. Intraepidermal lymphocytes is
psoriatic lesions are activated GMP-17
(TIA-1)+CD8+CD3+ CTLs as
determined by phenotypic analysis. J
Cutan Pathol 1998; 25: 79-88.
Picker LJ, Kishimoto TK, Smith CW
et al. ELAM-1 is an adhesion
molecule for skin–homing T cells.
Nature 1991; 349: 796-9.
Picker LJ, Treer JR, Ferguson-Darnell
B et al. Control of lymphocyte
recirculation in man. Differential
regulation of peripheral lymph node
homing receptor L-selection on T cells
during the virgin to memory cells
transition. J Immunol 1993; 150:
-21.
Fuhlbrigge RC, Kieffer JD,
Armerding D, Kupper TS. Cutaneous
lymphocyte antigen is a specialized
form of PSGL-1 expressed on skin–
homing T cells. Nature 1997; 389:
-81.
Gottlieb AB, Lifshitz B, Fu SM et al.
Expression of HLA-DR molecules by
keratinocytes, and presence of
Langerhans cells in the dermal
infiltrate of active psoriatic plaques. J
Exp Med 1986; 164: 1013-28.
Krueger JG. Pathogenic interactions of
keratinocytes and T lymphocytes in
psoriasis. In: Roenigk HH, Maibach
HI, eds. Psoriasis. New York: Marcel
Dekker; 1998. p. 315-27.
Worne-Smith T, Nickoloff BJ. Dermal
injection of immunocytes induces
psoriasis. J Clin Invest 1996; 98:
-87.
Heng MC, Kloss SG, Kuehn CS,
Chase DG. Significance and
pathogenesis of basal keratinocyte
herniations in psoriasis vulgaris. J
Invest Dermatol 1986; 87: 335-47.
Gillitzer R, Ritter U, Goebeler M,
Brocker EB. Differential expression of
GRO-a and IL-8 mRNA in psoriasis: a
model for neutrophil migration and
accumulation in vivo. J Invest
Dermatol 1996; 107: 778-82.
Cole MS, Stellrecht KE, Shi JD et al.
HuM291, a humanized anti-CD3
antibody, is immunosuppressive to T
cells while exhibiting reduced
mitogenicity in vitro. Transplantation
; 68: 563-71.
Bachelez H, Flageul B, Dubertret L et
al. Treatment of recalcitrant plaque
psoriasis with a humanized nondepleting
antibody to CD4. J
Autoimmun 1998; 11: 53-62.
Gottlieb A, Lebwohi M, Shirin S et al.
Anti–CD4 monoclonal antibody
treatment of moderate to serve
psoriasis vulgaris: results of a pilot,
multicentre multiple-dose, placebocontrolled
study. J Am Acad Dermatol
; 43: 595-604.
Abrams JR, Lebwohl MG, Guzzo CA
et al. CTAL4Ig mediated blockade to
T cell costimulation in patients with
psoriasis vulgaris. J Clin Invest 1990;
; 1243-52.
Ellis CN, Krueger GG. Treatment of
chronic plaque psoriasis by selective
targeting of memory effector T
lymphocytes. N Engl J Med 2000;
: 248-55.
Krueger JG, Walters IB, Miyazawa M
et al. Successful in vivo blockade of
CD 25 (high affinity interleukin 2
receptor) on T cells by administration
of humanized anti-TAC antibody to patient with psoriasis. J Am Acad
Dermatol 2000; 43: 448-58.
Owen C, Harrison PV. Successful
treatment of severe psoriasis with
basiliximab, an interleukin-2 receptor
monoclonal antibody. Clin Exp
Dermatol 2000; 25: 195-7.
Mrowietz U, Zhu K, Christopher E.
Treatment of severe psoriasis with
anti-CD25 monoclonal antibodies.
Arch Dermatol 2000; 136: 675-6.
Gottlieb SL, Gilleaudeau P, Johnson R
et al. Response of psoriasis to a
lymphocyte-selective toxin
(DAB389IL-2) suggests a primary
immune, but not keratinocyte,
pathogenic basis. Nat Med 1995; 1:
-7
Bagel J. Garland WT, Berneman D et
al. Administration of DAB389IL-2 to
patient with recalcitrant psoriasis: a
double blind phase II multicentre trial.
J Am Acad Dermatol 1998; 38; 938-
Trepicchio WL, Ozawa M, Walters IB
et al. Interleukin-11 therapy
selectively down regulates type 1
cytokine proinflammatory pathways in
psoriasis lesions. J Clin Invest 1999;
: 1527-37.
Asadullah K, Docke WD, Ebeling M
et al. Interleukin 10 treatment of
psoriasis: clinical results of phase 2
trial. Arch Dermatol 1999; 135: 187-
Asadullah K, Sterry W, Stephanek K
et al. IL-10 is a key cytokine in
psoriasis. Proof of principle by IL-10
therapy: a new therapeutic approach. J
Clin Invest 1998; 101: 783-94.
Oh CJ, Das KM, Gottlieb AB.
Treatment with anti-tumour necrosis
factor a (TNF-a) monoclonal antibody
dramatically decrease the clinical
activity of psoriasis lesions. J Am
Acad Dermatol 2000; 42: 829-30.
Mease PJ, Goffe BS, Metz J et al.
Etanercept in the treatment of psoriatic
arthritis and psoriasis: a randomized
trial. Lancet 2000; 356: 385-90.
Lohner ME, Krueger G, Gottlieb A et
al. Clinical trials of a fully human
anti-IL8 antibody for the treatment of
psoriasis. Br J Dermatol 1999; 141:
